Top Links

Articles Related to pharmaceuticals

Pharmacokinetics, Biotransformation, Distribution and Excretion of Empagliflozin, a Sodium-Glucose Co-Transporter (SGLT 2) Inhibitor, in Mice, Rats, and Dogs

The metabolism, pharmacokinetics, excretion and distribution of a sodium-glucose co-transporter (SGLT 2) inhibitor, empagliflozin, were studied in mice, rats and beagle dogs following a single oral or intravenous administration of [14C]-empagliflozin. Empagliflozin was well absorbed in all species after oral administration.
View complete article: PDF  |  Full-text

Croscarmellose Sodium Efficiency in the Development of a Generic Capsule Formulation of Piroxicam, Comparable Dissolution Profile to the Innovator Product, Feldene

The objective of this study was to evaluate the encapsulation performance of Croscarmellose sodium, a superdisintegrant in a low-dose, poor-solubility drug formulation and the in-vitro dissolution performance of the Piroxicam capsules. Preparation, characterization and evaluation of the effects of the different concentrations of carmellose sodium and the amount of dried starch on in-vitro dissolution of Piroxicam capsules. Piroxicam was chosen for its very low solubility in biological fluids, which result in poor systemic bioavailability after oral administration. Piroxicam can be categorized as Class II drugs according to the Biopharmaceutics Classification System.
View complete article: PDF  |  Full-text

Anti-Arthritic Efficacy And Safety Of Crominex 3+ (Trivalent Chromium, Phyllanthus emblica Extract, And Shilajit) In Moderately Arthritic Dogs

The present investigation was undertaken to evaluate the therapeutic efficacy and safety of Crominex 3+ (a complex of trivalent chromium, Phyllanthus emblica (Amla) extract and purified Shilajit) in moderately arthritic dogs.
View complete article: PDF  |  Full-text  | Digital
 
 

Anti-Inflammatory and Anti-Arthritic Efficacy and Safety of Purified Shilajit in Moderately Arthritic Dogs

The objective of this investigation was to evaluate the efficacy and safety of purified Shilajit in moderately arthritic dogs. Ten client-owned dogs in a randomized double-blinded study received either a placebo or Shilajit (500 mg) twice daily for a period of five months. Dogs were evaluated each month for physical condition (body weight, body temperature, heart rate, and respiration rate) and pain associated with arthritis (overall pain, pain from limb manipulation, and pain after physical exertion).
View complete article: PDF  |  Full-text  | Digital
 
 


Editorial Board Members Related to pharmaceuticals

Natasa Skalko-Basnet

Professor
Department of Pharmacy
University of Tromso
Norway

UMA D PALANISAMY

Associate Professor
Department of Biomedical Science
Jeffrey Cheah School of Medicine and Health Sciences
Monash Universtiy
Malaysia

Jiang He

Associate Professor
Department of Radiology and Medical Imaging
University of Virginia
United States

Yi-Wen Liu

Professor
Department of M icrobiology, Immunology and Biopharmaceuticals
National Chiayi University
Taiwan

Anthony Joseph Berdis

Assistant Professor
Departments of Chemistry and Biology
Cleveland State University
United States

JANAK PADIA

Associate Professor
Center of Biomolecular Therapeutics
University of Maryland
United States

XIAOYANG QI

Associate Director
Division of Hematology-Oncology
Department of Internal Medicine
University of Cincinnati
United States

KAZI MOHSIN

Assistant Professor
Department of Pharmaceutics
King Saud University
Saudi Arabia

Sarah Hall

Senior Lecturer
Department of Life Sciences
Anglia Ruskin University
United Kingdom

SAJA H. HAMED

Associate Professor
Department of Pharmaceutics and Pharmaceutical Technology
Hashemite University
Jordan
Submit Manuscript